Immunovant, Inc. (BOATS:IMVT) Financings

Immunovant, Inc.

Financings

RaiseDate
Public offering of common stock
Announced: about US$550M · US$21 a share · Leerink Partners
Dealers: Leerink Partners (lead)
Buyers: Roivant Sciences Ltd.
Insiders: Roivant Sciences Ltd., the controlling stockholder, has agreed to purchase shares in the offering
Use of proceeds: Fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 in Graves’ Disease
Dec 11, 2025
Private placement of shares of common stock
Announced: about US$450M · US$20 a share
Buyers: Roivant
Use of proceeds: Advancement of its development pipeline, working capital and other general corporate purposes
Jan 13, 2025

Read by 6ix AI from the company's releases